4/2
08:00 am
imrx
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
Medium
Report
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
3/24
08:09 am
imrx
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $13.00 price target on the stock.
Medium
Report
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $13.00 price target on the stock.
3/21
04:30 pm
imrx
Immuneering Corporation Announces Grant of Inducement Award
Medium
Report
Immuneering Corporation Announces Grant of Inducement Award
3/21
09:05 am
imrx
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
High
Report
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
3/20
05:05 pm
imrx
Immuneering GAAP EPS of -$0.58 [Seeking Alpha]
High
Report
Immuneering GAAP EPS of -$0.58 [Seeking Alpha]
3/20
04:05 pm
imrx
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Medium
Report
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
3/20
07:00 am
imrx
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
Low
Report
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
2/6
01:31 pm
imrx
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Low
Report
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
2/6
08:11 am
imrx
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab) [Yahoo! Finance]
Low
Report
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab) [Yahoo! Finance]
2/6
07:00 am
imrx
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Low
Report
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
2/3
04:51 pm
imrx
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/3
04:05 pm
imrx
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Medium
Report
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
1/13
11:12 am
imrx
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
Low
Report
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
1/13
08:00 am
imrx
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Medium
Report
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
1/8
06:59 pm
imrx
Why Is Immuneering Stock Trading Higher On Tuesday? [Yahoo! Finance]
Medium
Report
Why Is Immuneering Stock Trading Higher On Tuesday? [Yahoo! Finance]
1/8
08:00 am
imrx
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $13.00 price target on the stock.
Medium
Report
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $13.00 price target on the stock.